Exploring Microalgae as a Novel Resource for Hepatocellular Carcinoma Therapy

Sik Yoon1, Kok Keong Tan2, Won Hoon Song3

  • 1Department of Anatomy, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea.

Insights

Microalgae offer a promising natural source for novel hepatocellular carcinoma (HCC) therapies. Their compounds show potential against HCC, paving the way for advanced cancer treatment strategies.

Area of Science:

  • Biomedical applications
  • Marine biotechnology
  • Cancer therapeutics

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
  • Current HCC treatments face challenges including limited efficacy and therapeutic resistance due to tumor heterogeneity.
  • Novel therapeutic strategies are urgently needed for effective HCC management.

Purpose of the Study:

  • To review the biomedical potential of microalgae in cancer therapy, specifically for HCC.
  • To highlight microalgae as a source of anticancer compounds and a platform for novel therapeutics.
  • To explore future directions for microalgae-based HCC treatments.

Main Methods:

  • This review synthesizes findings from preclinical studies on microalgae and HCC.
  • It examines the unique properties of microalgae, including bioactive metabolites and oxygen-generating capabilities.
  • The review discusses biotechnological enhancement and formulation strategies for microalgal therapeutics.

Main Results:

  • Preclinical evidence indicates microalgae possess significant chemopreventive and anticancer properties against HCC.
  • Microalgae offer a versatile platform for developing next-generation cancer therapeutics.
  • Their multifunctional nature supports applications in drug delivery and immunotherapy.

Conclusions:

  • Microalgae show considerable promise for developing innovative therapeutic strategies against HCC.
  • Biotechnological advancements can enhance the production of microalgal-derived bioactive compounds.
  • Future applications include embolic agents and immunotherapy delivery systems for synergistic antitumor effects.